title: Resveratrol administration increases Transthyretin protein levels ameliorating AD features- importance of transthyretin tetrameric stability.
abstract: Previous in vivo work showed that resveratrol has beneficial effects in the AD pathology, resulting in increased expression of transthyretin (TTR). TTR binds Aβ peptide avoiding its aggregation and toxicity, and is reduced in the CSF and plasma, in AD. Further, resveratrol binds TTR, stabilizing the native TTR tetrameric structure. To further explore the mechanism of neuroprotection conferred by TTR in AD, resveratrol was administrated, in the diet, to 5-8 months old AD transgenic female mice carrying just one copy of the mouse TTR gene, for two months. Effects in brain Aβ burden were evaluated by immunohistochemistry, and in total brain Aβ levels by ELISA, showing a striking decrease in both parameters in treated animals. In addition, total brain LRP1 protein levels were increased in treated animals, although its gene expression was unaltered. To further understand the mechanism(s) underlying such improvement in AD features, we measured TTR plasma levels showing that TTR increased in resveratrol-treated mice, whereas liver TTR gene transcription was not altered. These results strengthen the stability hypothesis, which postulates that TTR is unstable in AD leading to accelerated clearance and lower levels. Therefore, resveratrol which stabilizes the TTR tetramer results in TTR normalized clearance, thus increasing the protein plasma levels. In turn, stabilized TTR binds more strongly to Aβ peptide, avoiding its aggregation. Our results represent a step forward to the understanding of the mechanism underlying TTR protection in AD and highlight the possibility of using TTR stabilization as a therapeutic target in AD.
authors.affiliation: IBMC - Instituto de Biologia Celular e Molecular.|i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
authors.forename: L M
authors.initials: LM
authors.lastname: Santos
authors.affiliation: IBMC - Instituto de Biologia Celular e Molecular.|i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.|ESTSP - Department of Health Sciences, School of Allied Health Technologies, Polytechnic Institute of Porto, Portugal.
authors.forename: D
authors.initials: D
authors.lastname: Rodrigues
authors.affiliation: IBMC - Instituto de Biologia Celular e Molecular.|i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.|Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
authors.forename: M
authors.initials: M
authors.lastname: Alemi
authors.affiliation: IBMC - Instituto de Biologia Celular e Molecular.|i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.|ESTSP - Department of Health Sciences, School of Allied Health Technologies, Polytechnic Institute of Porto, Portugal.
authors.forename: S C
authors.initials: SC
authors.lastname: Silva
authors.affiliation: IBMC - Instituto de Biologia Celular e Molecular.|i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
authors.forename: C A
authors.initials: CA
authors.lastname: Ribeiro
authors.affiliation: IBMC - Instituto de Biologia Celular e Molecular.|i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
authors.forename: I
authors.initials: I
authors.lastname: Cardoso
keywords: A-Beta peptide; Alzheimer’s Disease); LRP1; Neuroprotection; TTR tetrameric stability; Transthyretin